Daniel Reimer

3.5k total citations
79 papers, 2.5k citations indexed

About

Daniel Reimer is a scholar working on Molecular Biology, Reproductive Medicine and Oncology. According to data from OpenAlex, Daniel Reimer has authored 79 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Molecular Biology, 31 papers in Reproductive Medicine and 23 papers in Oncology. Recurrent topics in Daniel Reimer's work include Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (8 papers) and RNA modifications and cancer (8 papers). Daniel Reimer is often cited by papers focused on Ovarian cancer diagnosis and treatment (31 papers), Endometrial and Cervical Cancer Treatments (8 papers) and RNA modifications and cancer (8 papers). Daniel Reimer collaborates with scholars based in Austria, Germany and United States. Daniel Reimer's co-authors include Jörg Striessnig, Alain G. Zeimet, Christian Marth, Manfred Grabner, Alexandra Koschak, Hartmut Glossmann, Irene Huber, Nicole Concin, Jutta Engel and Matteo E. Mangoni and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Daniel Reimer

77 papers receiving 2.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Reimer Austria 27 1.7k 642 593 494 394 79 2.5k
Kazuhiro Ogi Japan 27 1.4k 0.8× 349 0.5× 612 1.0× 67 0.1× 350 0.9× 74 2.3k
Dalil Hamroun France 24 2.1k 1.3× 361 0.6× 273 0.5× 414 0.8× 250 0.6× 60 3.5k
Ricardo Martínez United States 17 2.4k 1.5× 494 0.8× 452 0.8× 92 0.2× 490 1.2× 41 3.4k
Lieve Umans Belgium 28 1.9k 1.1× 285 0.4× 350 0.6× 50 0.1× 237 0.6× 49 2.8k
Peter Hein Germany 18 1.2k 0.7× 401 0.6× 688 1.2× 62 0.1× 364 0.9× 34 2.1k
Simon J. Rhodes United States 34 3.2k 1.9× 173 0.3× 151 0.3× 305 0.6× 319 0.8× 87 4.2k
Michelle Russell United States 10 1.1k 0.7× 598 0.9× 423 0.7× 27 0.1× 324 0.8× 16 2.5k
Sergey V. Shmelkov United States 19 1.5k 0.9× 288 0.4× 1.1k 1.9× 37 0.1× 468 1.2× 25 2.9k
Claudia A. Landis United States 11 1.2k 0.7× 161 0.3× 412 0.7× 68 0.1× 255 0.6× 13 2.5k
Alessandro Fatatis United States 31 1.4k 0.8× 502 0.8× 1.4k 2.3× 45 0.1× 527 1.3× 68 3.3k

Countries citing papers authored by Daniel Reimer

Since Specialization
Citations

This map shows the geographic impact of Daniel Reimer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Reimer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Reimer more than expected).

Fields of papers citing papers by Daniel Reimer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Reimer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Reimer. The network helps show where Daniel Reimer may publish in the future.

Co-authorship network of co-authors of Daniel Reimer

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Reimer. A scholar is included among the top collaborators of Daniel Reimer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Reimer. Daniel Reimer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fiegl, Heidi, Daniel Reimer, Katharina Leitner, et al.. (2024). BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer. Clinical Epigenetics. 16(1). 171–171. 3 indexed citations
3.
Wieser, Verena, Irina Tsibulak, Daniel Reimer, et al.. (2023). An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer. Gynecologic Oncology. 170. 290–299. 9 indexed citations
4.
Leitner, Katharina, Irina Tsibulak, Verena Wieser, et al.. (2020). Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer. Scientific Reports. 10(1). 20412–20412. 15 indexed citations
5.
Kramer, Mario W., Jürgen Serth, Jörg Hennenlotter, et al.. (2018). Calgranulin A (S100A8) Immunostaining: A Future Candidate for Risk Assessment in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC). Advances in Therapy. 35(11). 2054–2068. 7 indexed citations
6.
Bekos, Christine, Christoph Grimm, Thomas Brodowicz, et al.. (2017). Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma – a multicenter study. Scientific Reports. 7(1). 14474–14474. 16 indexed citations
7.
Marth, Christian, Daniel Reimer, & Alain G. Zeimet. (2017). Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Annals of Oncology. 28(suppl_8). viii36–viii39. 70 indexed citations
8.
Wieser, Verena, et al.. (2016). PD-1 and PD-L1 expression in ovarian cancer. Annals of Oncology. 27. viii3–viii3. 1 indexed citations
9.
10.
Azim, Samira Abdel, Susanne Sprung, Daniel Reimer, et al.. (2016). Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer. Oncotarget. 7(24). 37205–37214. 6 indexed citations
11.
Sehouli, Jalid, Alexander Reinthaller, Christian Marth, et al.. (2014). Intra- and postoperative catumaxomab in patients with epithelial ovarian cancer: safety and two-year efficacy results from a multicentre, single-arm, phase II study. British Journal of Cancer. 111(8). 1519–1525. 13 indexed citations
12.
Hofstetter, Gerda, Astrid Berger, Elisabeth Müller‐Holzner, et al.. (2011). Clinical Relevance of TAp73 and ΔNp73 Protein Expression in Ovarian Cancer. International Journal of Gynecological Pathology. 30(6). 527–531. 9 indexed citations
13.
Reimer, Daniel, Michael Hubalek, Helena Kiefel, et al.. (2011). Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer. Oncogene. 30(38). 4038–4049. 38 indexed citations
14.
Reimer, Daniel, Michael Hubalek, Svenja Riedle, et al.. (2010). E2F3a Is Critically Involved in Epidermal Growth Factor Receptor–Directed Proliferation in Ovarian Cancer. Cancer Research. 70(11). 4613–4623. 30 indexed citations
15.
Zeimet, Alain G., Daniel Reimer, Lukas Schwentner, et al.. (2010). Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer. Cancer Immunology Immunotherapy. 59(12). 1813–1823. 3 indexed citations
16.
Berger, Regina, Heidi Fiegl, Hans H. Goebel, et al.. (2010). Toll‐like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Science. 101(4). 1059–1066. 74 indexed citations
17.
Reimer, Daniel, Elisabeth Müller‐Holzner, Christian Marth, et al.. (2010). Breast Cancer in Women: Evaluation of Benign and Malignant Axillary Lymph Nodes with Contrast-Enhanced Ultrasound. Ultraschall in der Medizin - European Journal of Ultrasound. 31(1). 63–67. 18 indexed citations
18.
Reimer, Daniel, Annemarie Wiedemair, Christian Marth, et al.. (2008). Expression of coxsackie-adenovirus receptor is related to estrogen sensitivity in breast cancer. Breast Cancer Research and Treatment. 116(1). 103–111. 13 indexed citations
19.
Reimer, Daniel, Annemarie Wiedemair, Nicole Concin, et al.. (2007). Soluble isoforms but not the transmembrane form of coxsackie‐adenovirus receptor are of clinical relevance in epithelial ovarian cancer. International Journal of Cancer. 120(12). 2568–2575. 19 indexed citations
20.
Matthes, Jan, L.T. Yıldırım, Georg Wietzorrek, et al.. (2004). Disturbed atrio-ventricular conduction and normal contractile function in isolated hearts from Ca v 1.3-knockout mice. Naunyn-Schmiedeberg s Archives of Pharmacology. 369(6). 554–562. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kazuhiro Ogi Breakdown of academic impact, for papers by Dalil Hamroun Breakdown of academic impact, for papers by Ricardo Martínez Breakdown of academic impact, for papers by Lieve Umans Breakdown of academic impact, for papers by Peter Hein Breakdown of academic impact, for papers by Simon J. Rhodes Breakdown of academic impact, for papers by Michelle Russell Breakdown of academic impact, for papers by Sergey V. Shmelkov Breakdown of academic impact, for papers by Claudia A. Landis Breakdown of academic impact, for papers by Alessandro Fatatis
Rankless by CCL
2026